Xcout IntelArtelo Biosciences, Inc.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Subscribe to see Artelo Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Artelo Biosciences, Inc. at a glance
Artelo Biosciences, Inc. is a biotech company headquartered in Solana Beach, United States. It is publicly listed (ARTL) with a market capitalisation of $2.5M. Xcout tracks 25 named people at Artelo Biosciences, Inc., including Gregory D. Gorgas (President, Chief Executive Officer, Secretary & Director).
Artelo Biosciences, Inc. leadership
- Gregory D. GorgasPresident, Chief Executive Officer, Secretary & Director
- Gregory GorgasPresident, Chief Executive Officer and on our board of directors
- Mark E. SpringChief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer
- Andrew YatesSenior Vice President & Chief Scientific Officer
- Steven D. ReichChief Medical Officer
- Connie MatsuiChair
19 more named people on record for Artelo Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Artelo Biosciences, Inc. competitors
A few of Artelo Biosciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
International Bioceutical Co., LLC operates as a cannabinoid life sciences company that manufactures and supplies EU-GMP certified active pharmaceutical ingredients (APIs). The company serves pharmaceutical companies, nutraceutical brands, and animal health organizations worldwide by providing cannabinoid-based ingredients and product development support for human and veterinary use.
ARTBIO is a biotechnology company developing targeted alpha-particle radioligand therapies for cancer, including treatments intended to selectively deliver radioactive payloads to tumor cells. Its work is aimed at serving oncology patients and healthcare providers treating solid tumors.
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Get Artelo Biosciences, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Artelo Biosciences, Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access